Bone Biologics (BBLG) Income from Continuing Operations (2010 - 2026)
Bone Biologics (BBLG) posted quarterly Income from Continuing Operations of 773475.0 for Q4 2025, up 52.3% year-over-year from 507856.48 in Q4 2024, and up 15.03% quarter-over-quarter from 910246.0 in Q3 2025.
Powered by 
Analysis
Bone Biologics (BBLG) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Bone Biologics (BBLG) has reported Income from Continuing Operations for 16 consecutive years, with 773475.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Income from Continuing Operations rose 52.3% year-over-year to 773475.0; the TTM figure through Dec 2025 stood at 3443589.0 (up 19.68% YoY), while the FY2025 annual figure was 27923958.0, down 8.04% from the prior year.
- Income from Continuing Operations rose to 773475.0 in Q4 2025 per BBLG's latest filing, from 910246.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 176137.0 in Q4 2021 and bottomed at 21639093.0 in Q4 2022.
- Historically, Income from Continuing Operations has averaged 3159135.3 across 5 years, with a median of 906763.5 in 2024.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 12185.38% — and 2024, when it surged 92.48%.
- Bone Biologics' Income from Continuing Operations stood at 176137.0 in 2021, then sank by 12185.38% to 21639093.0 in 2022, then gained by 0.32% to 21570659.0 in 2023, then soared by 92.48% to 1621605.0 in 2024, then soared by 52.3% to 773475.0 in 2025.
- Business Quant data shows BBLG's Income from Continuing Operations at 773475.0 in Q4 2025, 910246.0 in Q3 2025, and 741421.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.52 Bn | 133.66 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.69 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.63 Bn | 59.45 Bn | 1.37 Bn | 600.00 Mn |
| 4 | Moderna | 59.30 Bn | 54.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.41 Bn | 44.41 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.45 Bn | 35.35 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.29 Bn | 31.98 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Bone Biologics | 1.00 Mn | 1.00 Mn | - | -773,594.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -773,594.00 |
| Dec 31, 2025 | -773,475.00 |
| Sep 30, 2025 | -910,246.00 |
| Jun 30, 2025 | -741,421.00 |
| Mar 31, 2025 | -1.02 Mn |
| Dec 31, 2024 | -1.62 Mn |
| Sep 30, 2024 | -1.22 Mn |
| Jun 30, 2024 | -794,518.00 |
| Mar 31, 2024 | -903,281.00 |
| Dec 31, 2023 | -1.16 Mn |
| Sep 30, 2023 | -2.08 Mn |
| Jun 30, 2023 | -3.04 Mn |
| Mar 31, 2023 | -3.15 Mn |
| Dec 31, 2022 | -1.29 Mn |
| Sep 30, 2022 | -1.22 Mn |
| Jun 30, 2022 | -437,827.00 |
| Mar 31, 2022 | -689,499.00 |
| Dec 31, 2021 | -176,137.00 |
| Sep 30, 2021 | -509,303.00 |
| Jun 30, 2021 | -491,898.00 |